Can Pentraxin-3 be a Candidate Marker in the Follow-Up of the Patients With Behçet’s Disease?

Abstract

Objectives: This study aims to assess the level of pentraxin-3 (PTX-3) as an inflammatory marker and compare it with C-reactive protein (CRP) levels in patients with Behçet's disease (BD). Patients and methods: Forty-two patients with BD (15 males, 27 females; mean age 39.7±8.6 years; range 20 to 64 years) and 42 age-and sex-matched healthy controls (14 males, 28 females; mean age 40.8±8.2 year; range 25 to 60 years) were included in the study. Serum CRP and plasma PTX-3 levels were measured. Subgroup analyses were performed according to clinical manifestations of patients with BD. Results: Both PTX-3 and CRP levels were significantly higher in patients with BD than controls (1.33±0.29 vs 0.85±0.12, p<0.05 for PTX-3 and 0.71±0.13 vs 0.27±0.03, p<0.001 for CRP, respectively). Area under the curve was 0.633±0.062 vs 0.729±0.05, respectively. Mean PTX-3 and CRP levels were 1.1 vs 1.5, p=0.5; 0.5 vs 0.9, p=0.5; respectively, in patients with mucocutaneous involvement alone and with other involvements, whereas they were 0.9 vs 1.6, p=0.1; 0.5 vs 0.8, p=0.3; respectively, in patients with and without peripheral arthritis, and were 1.7 vs 0.9, p=0.06; 1.0 vs 0.5, p=0.07; respectively, in patients with and without uveitis. Conclusion: Although PTX-3 levels were higher in patients with BD than healthy controls, sensitivity and specificity of PTX-3 was not different than CRP in patients with BD.

Pentraxin 3 levels and correlation with disease severity in patients with acute rheumatic fever

“…The two most important characteristics of PTX3 are that it is locally produced in the endothelium and it reaches peak levels faster than CRP. [ 6 , 17 , 18 ] It is reported that PTX3 level is elevated in cardiovascular diseases and can be regarded as a biomarker of cardiovascular disease in the general population. [ 18 ] High serum PTX3 levels have also been associated with increased cardiovascular complications in conditions such as Cushing’s and Behçet’s diseases and in hemodialysis patients.…”

“…It belongs to the same protein family as C-reactive protein (CRP); however, while CRP is mainly synthesized in the liver, PTX3 is mostly produced locally in the area of inflammation. 5,6 PTX3 has been associated with inflammation in cardiovascular diseases such as heart failure, atherosclerosis, acute coronary syndrome, peripheral vascular diseases, and rheumatic mitral valve stenosis. 4,[7][8][9] To our knowledge, there are no previous studies in the literature regarding serum PTX3 levels in ARF patients.…”